Search for a trial

A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line platinum/pemetrexed-based chemotherapy

The main purpose of this study is to assess whether the study drug anetumab ravtansine is more effective than treatment with vinorelbine in patients with stage IV, mesothelin overexpressing malignant pleural mesothelioma. Efficacy will be measured…

A phase II trial of TTFields in addition to pemetrexed and cisplatin or carboplatin as first-line
treatment in malignant pleural mesothelioma

Primary Objective:* To determine if TTFields in combination with pemetrexed/platinum improves overall survival (OS) compared to historical control in patients with unresectable mesothelioma.Secondary Objectives:* To evaluate the overall response…

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma

Primary Efficacy Objectives• To compare the overall survival (OS) in subjects with malignant pleural mesothelioma receiving VS-6063 or placebo.• To compare the progression free survival (PFS) in subjects with malignant pleural mesothelioma receiving…

An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma

The primary objective is to determine the effect on progression-free survival (PFS) of adding MORAb-009 to the combination of pemetrexed and cisplatin in the treatment of subjects with unresectable malignant pleural mesothelioma (MPM). (Protocol ch…

A randomized phase I/II study of standard chemotherapy (cisplatin and pemetrexed) with or without Axitinib in patients with malignant mesothelioma:
interim biopsy analysis and Dynamic Contrast Enhanced MRI to determine efficacy.

To test the impact of the addition of axitinib to standard chemotherapy treatment on histology samples

An Open Label Phase II Multicentre Clinical Trial of Single Agent VELCADETM (Bortezomib) in Patients with Malignant Pleural Mesothelioma

To find activity in this new class of drugs

A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study

Primary Objective* To determine the DCR (disease control rate) at 12 weeks of nivolumab monotherapy in patients with progressive MPM.Secondary Objectives* To determine the safety of nivolumab monotherapy in patients with progressive MPM* To…

PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients.

Primary: 1. To determine the objective response rate (ORR), defined by Modified (i)RECIST criteria for pleural mesothelioma, of the combination of pembrolizumab - lenvatinib in pre-treated patients with MPM. Secondary:1. To describe the safety of…

A randomized, open-label phase II/III study with dendritic cells loaded with allogeneic tumour cell lysate (PheraLys) in subjects with mesothelioma as maintenance treatment (MesoPher) after chemotherapy

The primary objective of this study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to…

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma

To assess the feasibility of administering DCBI after CRS-HIPEC in patients with malignant peritoneal mesothelioma.

Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase II study. ;NVALT 19

Primary objectives:1. Determine the potential improvement of the duration of progression-free survival by maintenance treatment with gemcitabine. Secondary objectives:1. To compare the objective radiological response (ORR) rate2. To compare overall…

Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study

The primary objective of the study is the disease control rate (DCR) at 12 weeks of the combination treatment of Nivolumab and Ipilimumab in patients with progressive MPM.The secondary objectives are:- to determine the safety profile of the…